# US 2026/0215963 A1 · Treatment of ocular injuries using microbots

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0215963 A1
- Document ID: US20260215963A1
- Status: Published application
- Kind: A1
- Application number: 19/459,690
- Filed: 2026-01-26
- Published: 2026-07-30
- Earliest claimed: 2025-01-27
- Assignees: Applied Research Associates, Inc.
- Applicants: Applied Research Associates, Inc.
- Inventors: Louis William Rogowski
- Web page: https://patentgrep.com/patent/US20260215963A1

## CPC

- A61F 9/0026: {Ophthalmic product dispenser attachments to facilitate positioning near the eye}
- A61B 34/30: Surgical robots
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Systems, methods, and computer-readable media for delivering drugs to an ocular region. A system for delivering drugs may include a microbot, the microbot comprising a biocompatible body, a plurality of magnetic particles, and a drug payload. The microbot may be configured to be navigated within a biofluid to a target ocular region via a magnetic control system. The microbot may be configured to automatically release the drug payload into a surrounding environment of the target ocular region in response to a condition being met. The drug payload may comprise a thrombolytic compound configured to degrade coagulated blood upon the release of the drug payload into the surrounding environment. Further, the drug payload may comprise molecules configured to promote survivability of retinal ganglion cells (RGCs) upon the release of the drug payload into the surrounding environment.

## Claims

### Claim 1

A microbot configured for delivering drugs to an ocular region, the microbot comprising:
a biocompatible body;
a plurality of magnetic particles dispersed throughout the biocompatible body; and
a drug payload dispersed throughout the biocompatible body,
wherein the microbot is configured to be navigated within a biofluid to a target ocular region via a magnetic control system,
wherein the microbot is configured to automatically release the drug payload into a surrounding environment of the target ocular region in response to a condition being met.

### Claim 2 (depends on 1)

The microbot of claim 1, wherein the drug payload comprises a thrombolytic compound configured to degrade coagulated blood upon the release of the drug payload into the surrounding environment.

### Claim 3 (depends on 2)

The microbot of claim 2, wherein the thrombolytic compound at least comprises tissue plasminogen activator (tPA) or streptokinase.

### Claim 4 (depends on 1)

The microbot of claim 1, wherein the drug payload comprises molecules configured to promote survivability of retinal ganglion cells (RGCs) upon the release of the drug payload into the surrounding environment.

### Claim 5 (depends on 4)

The microbot of claim 4, wherein the molecules are at least brain-derived neurotrophic factor (BDNF) protein molecules.

### Claim 6 (depends on 1)

The microbot of claim 1, wherein the condition is the surrounding environment reaching a predetermined temperature.

### Claim 7 (depends on 6)

The microbot of claim 6, wherein the drug payload comprises chemical additives configured to modulate a release rate of the release of the drug payload into the surrounding environment.

### Claim 8 (depends on 7)

The microbot of claim 7, wherein the chemical additives are co-polymer additives, wherein the release of the drug payload occurs upon the co-polymer additives detecting the predetermined temperature of the surrounding environment.

### Claim 9 (depends on 7)

The microbot of claim 7, wherein the release rate of the drug payload is a controlled rate such that the drug payload is uniformly released over a length of time upon the condition being met.

### Claim 10 (depends on 1)

The microbot of claim 1, wherein the condition is the surrounding environment reaching a predetermined pH level.

### Claim 11 (depends on 1)

The microbot of claim 1, wherein the plurality of magnetic particles and the drug payload are dispersed throughout the biocompatible body.

### Claim 12 (depends on 1)

The microbot of claim 1, wherein the biocompatible body is an alginate hydrogel.

### Claim 13 (depends on 11)

The microbot of claim 11, wherein the microbot has a width between 1 μm to 200 μm.

### Claim 14

A system configured for delivering drugs to an ocular region, comprising:
a microbot, comprising:
a biocompatible body;
a plurality of magnetic particles dispersed throughout the biocompatible body;
a drug payload dispersed throughout the biocompatible body; and
a magnetic control system, wherein the magnetic control system is configured to navigate the microbot within a biofluid to a target ocular region,
wherein the microbot is configured to automatically release the drug payload into a surrounding environment of the target ocular region in response to a condition being met.

### Claim 15 (depends on 14)

The system of claim 14, wherein the magnetic control system comprises a plurality of Helmholtz coils, wherein selective rotation of the plurality of Helmholtz coils corresponds to selective movement of the microbot within the biofluid.

### Claim 16 (depends on 15)

The system of claim 15, wherein the magnetic control system is configured to navigate the microbot within the biofluid along any of an x-axis, a y-axis, or a z-axis.

### Claim 17 (depends on 16)

The system of claim 16, wherein the magnetic control system is configured to navigate the microbot to the target ocular region using closed-loop feedback.

### Claim 18 (depends on 14)

The system of claim 14, wherein the target ocular region is a location within a vitreous humor region.

### Claim 19 (depends on 14)

The system of claim 14, further comprising:
a second microbot, comprising:
a second biocompatible body;
a second plurality of magnetic particles dispersed throughout the second biocompatible body; and
a second drug payload dispersed throughout the second biocompatible body,
wherein the magnetic control system is configured to navigate the second microbot within the biofluid to the target ocular region,
wherein the second microbot is configured to automatically release the second drug payload into the surrounding environment of the target ocular region in response to the condition being met.

### Claim 20

A method for delivering drugs to an ocular region, the method comprising:
administering a plurality of microbots into an ocular component, each of the plurality of microbots comprising:
a biocompatible body;
a plurality of magnetic particles dispersed throughout the biocompatible body; and
a drug payload dispersed throughout the biocompatible body;
controlling the plurality of microbots via a magnetic control system, wherein the magnetic control system is configured to navigate the plurality of microbots within a biofluid to a target ocular region; and
releasing, automatically in response to a condition being met, the drug payload into a surrounding environment of the target ocular region.
